Results 51 to 60 of about 121,676 (256)

Etiology, Epidemiology, and Therapeutic Approaches for Primary Sclerosing Cholangitis in the Context of Concurrent Non-specific Inflammatory Bowel Diseases

Journal of Education, Health and Sport
Introduction: Primary sclerosing cholangitis (PSC) is a chronic, idiopathic disease characterized by persistent and progressive inflammation of the intrahepatic and/or extrahepatic bile ducts. This leads to fibrosis, cholestatic complications, and liver
Anna Olszewska, Karolina Matyja, Aleksandra Berner, Katarzyna Stencel, Karina Stelmaszak, Klaudia Marczyk, Paulina Polak, Maciej Pękała, Monika Polaszek, Marta Bogowska   +9 more
doaj   +1 more source

Association of ulcerative colitis, celiac disease, primary sclerosing cholangitis and liver cirrhosis in a young male

JGH Open, 2023
Inflammatory bowel diseases (IBD), including ulcerative colitis, are chronic autoimmune conditions characterized by inflammation of the digestive system.
Ahmad N. Alkhaledi, Isra Jadaan, Mohamad Zaher Sharfo, Tala Faysal, Yazane Abdallah, Ahmad Alhaj Ali   +5 more
doaj   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

wsq-primary hyperideals of a Krasner (m,n)-hyperring [PDF]

arXiv, 2023
In this paper we aim to introduce some hyperideals such as q-primary, (k,n)-absorbing q-primary, sq-primary, wsq-primary hyperideals.
arxiv  

Clinical Features, Differential Diagnosis and Treatment of IgG₄-Related Sclerosing Cholangitis

Архивъ внутренней медицины
The aim: To present the state-of-the-art of clinical features, differential diagnosis and treatment of IgG4-related sclerosing cholangitis.Key points: IgG4-sclerosing cholangitis is a fibrotic inflammatory disease affecting the intrahepatic and ...
A. K. Guseva, A. V. Okhlobystin
doaj   +1 more source

FIGO guideline on liver disease and pregnancy

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana, Virna Medina, Cynthia Maxwell, Ciara McCormick, Gloria Taliani, Ulrich Beuers, Deborah Money, Bo Jacobsson, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Graeme Smith, Lina Bergman, Sharleen O'Reilly, Patrick O'Brien, Mark Hanson, Mary Rosser, Claudio Sosa, Sumaiya Adam, Valerie Guinto, Liona Poon, Fionnuala McAuliffe, Catherine Williamson, on behalf of the FIGO Committee on Impact of Pregnancy on Long‐term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health   +24 more
wiley   +1 more source

Satellite number density profiles of primary galaxies in the 2dFGRS [PDF]

Mon.Not.Roy.Astron.Soc. 356 (2005) 1045-1052, 2004
We analyse the projected radial distribution of satellites around bright primary galaxies in the 2dFGRS. We have considered several primary-satellite subsamples to search for dependences of the satellite number density profile, \rho(r_p), on properties of satellites and primaries.
arxiv   +1 more source

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1 study) or advanced fibrosis due to metabolic‐associated fatty liver disease (MAFLD; phase 2a study).
Islam R. Younis, Elijah J. Weber, Cara Nelson, Ann R. Qin, Timothy R. Watkins, Ahmed A. Othman   +5 more
wiley   +1 more source

Update on primary sclerosing cholangitis [PDF]

Journal of Hepatology, 2013
Primary sclerosing cholangitis (PSC) remains one of the most challenging conditions of clinical hepatology. There has been a steady growth in research to overcome this fact and the present review aims at summarizing the most recently published literature.
Tom H. Karlsen, Tom H. Karlsen, Kirsten Muri Boberg, Kirsten Muri Boberg   +3 more
openaire   +4 more sources

The changing faces of cholangitis [version 1; referees: 2 approved]

F1000Research, 2016
A variety of diseases are included under the umbrella term ‘cholangitis’, including hepatobiliary diseases with an autoimmune pathogenesis (such as primary sclerosing cholangitis, primary biliary cholangitis, and IgG4-associated sclerosing cholangitis ...
Sum P. Lee, Joseph R. Roberts, Rahul Kuver   +2 more
doaj   +1 more source